KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBT (2018 - 2025)

Historic EBT for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$386000.0.

  • Castle Biosciences' EBT fell 10466.07% to -$386000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.9 million, marking a year-over-year decrease of 26982.4%. This contributed to the annual value of $21.6 million for FY2024, which is 13759.09% up from last year.
  • Latest data reveals that Castle Biosciences reported EBT of -$386000.0 as of Q3 2025, which was down 10466.07% from -$143000.0 recorded in Q2 2025.
  • Castle Biosciences' EBT's 5-year high stood at $8.3 million during Q3 2024, with a 5-year trough of -$29.2 million in Q1 2023.
  • For the 5-year period, Castle Biosciences' EBT averaged around -$9.0 million, with its median value being -$6.9 million (2023).
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 41031.09% in 2024, then plummeted by 95548.41% in 2025.
  • Over the past 5 years, Castle Biosciences' EBT (Quarter) stood at -$15.2 million in 2021, then tumbled by 35.67% to -$20.6 million in 2022, then skyrocketed by 87.64% to -$2.5 million in 2023, then soared by 410.31% to $7.9 million in 2024, then plummeted by 104.9% to -$386000.0 in 2025.
  • Its EBT was -$386000.0 in Q3 2025, compared to -$143000.0 in Q2 2025 and -$26.3 million in Q1 2025.